XML 29 R12.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Fair Value Measurement | 12 Months Ended
--- | ---
Dec. 31, 2023
Fair Value Disclosures [Abstract] |
Fair Value Measurement | Fair Value Measurement Available-for-sale marketable securities consisted of the following (in thousands):
|  | December 31, 2023
|  | Amortized Cost |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Estimated Fair Value
Asset-backed securities |  | $ | 3,512 |  |  | $ | — |  |  | $ | (8) |  |  | $ | 3,504 |
Corporate debt securities |  | 6,022 |  |  | 1 |  |  | (10) |  |  | 6,013 |
U.S. treasury securities |  | 175,996 |  |  | 200 |  |  | (12) |  |  | 176,184 |
Agency bonds |  | 16,119 |  |  | — |  |  | (16) |  |  | 16,103 |
Commercial paper |  | 15,826 |  |  | — |  |  | — |  |  | 15,826 |
Total marketable securities, available-for-sale |  | $ | 217,475 |  |  | $ | 201 |  |  | $ | (46) |  |  | $ | 217,630 |
|  | December 31, 2022
|  | Amortized Cost |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Estimated Fair Value
Asset-backed securities |  | $ | 1,146 |  |  | $ | — |  |  | $ | — |  |  | $ | 1,146 |
Corporate debt securities |  | 7,139 |  |  | — |  |  | (9) |  |  | 7,130 |
U.S. treasury securities |  | 111,469 |  |  | — |  |  | (934) |  |  | 110,535 |
Agency bonds |  | 2,783 |  |  | 2 |  |  | (1) |  |  | 2,784 |
Commercial paper |  | 7,004 |  |  | — |  |  | — |  |  | 7,004 |
Total marketable securities, available-for-sale |  | $ | 129,541 |  |  | $ | 2 |  |  | $ | (944) |  |  | $ | 128,599 |
As of December 31, 2023, 20 available-for-sale marketable securities with a fair market value of $29.1 million were in a gross unrealized loss position of $46.3 thousand. Based on our review of these marketable securities, we believe none of the unrealized loss is as a result of a credit loss as of December 31, 2023 because we do not intend to sell these securities and it is not more-likely-than-not that we will be required to sell these securities before the recovery of their amortized cost basis. The estimated fair value of our contractual maturities of available-for-sale debt securities were as follows (in thousands):
|  | December 31, 2023 |  | December 31, 2022
Due within one year |  | $ | 197,633 |  |  | $ | 114,353 |
Due after one year but within five years |  | 19,997 |  |  | 14,246 |
Total estimated fair value of contractual maturities, available-for-sale |  | $ | 217,630 |  |  | $ | 128,599 |
The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):
|  | December 31, 2023 |  | December 31, 2022
|  | Level 1 |  | Level 2 |  | Total estimated fair value |  | Level 1 |  | Level 2 |  | Total estimated fair value
Assets |  |  |  |  |  |  |  |  |  |  |  |
Cash equivalents |  |  |  |  |  |  |  |  |  |  |  |
Money market funds |  | $ | 22,142 |  |  | $ | — |  |  | $ | 22,142 |  |  | $ | 191,704 |  |  | $ | — |  |  | $ | 191,704 |
U.S. treasury securities |  | 2,000 |  |  | — |  |  | 2,000 |  |  | — |  |  | — |  |  | — |
Corporate debt securities |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Available-for-sale marketable securities |  |  |  |  |  |  |  |  |  |  |  |
Asset-backed securities |  | — |  |  | 3,504 |  |  | 3,504 |  |  | — |  |  | 1,146 |  |  | 1,146 |
Corporate debt securities |  | — |  |  | 6,013 |  |  | 6,013 |  |  | — |  |  | 7,130 |  |  | 7,130 |
U.S. treasury securities |  | 176,184 |  |  | — |  |  | 176,184 |  |  | 110,535 |  |  | — |  |  | 110,535 |
Agency bonds |  | 16,103 |  |  | — |  |  | 16,103 |  |  | 2,784 |  |  |  |  | 2,784 |
Commercial paper |  | — |  |  | 15,826 |  |  | 15,826 |  |  | — |  |  | 7,004 |  |  | 7,004 |
Total assets |  | $ | 216,429 |  |  | $ | 25,343 |  |  | $ | 241,772 |  |  | $ | 305,023 |  |  | $ | 15,280 |  |  | $ | 320,303 |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |
Derivative instruments |  |  |  |  |  |  |  |  |  |  |  |
Currency hedging contracts(1) |  | $ | — |  |  | $ | 9,480 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
(1) Based on observable market transactions of spot currency rates, forward currency rates or equivalently-termed instruments. Carrying amounts of the financial assets and liabilities are equal to the fair value. As of December 31, 2023, the derivative liabilities recorded within accrued expenses and other long-term liabilities were $2.9 million and $6.6 million, respectively. We had no available for sale securities that were classified within Level 3 as of December 31, 2023 and 2022. A contingent liability was assumed as part of the Antares acquisition related to TLANDO. The acquisition date fair value was measured using the income approach, specifically the probability weighted expected return method for the development milestone payments and the option pricing methodology using the Monte Carlo simulation for commercial milestone payments and royalty payments. Estimates and assumptions used in the Monte Carlo simulation include forecasted revenues, cost of debt, risk free rate, weighted average cost of capital, revenue market price risk and revenue volatility. Estimates and assumptions used in the income approach include the probability of achieving certain milestones and a discount rate. These unobservable inputs represent a Level 3 measurement because they are supported by little or no market activity and reflect our own assumptions in measuring fair value. Changes in the fair value subsequent to the acquisition date is recognized in our consolidated statements of income. In September 2023, we provided Lipocine notice of termination of the TLANDO license agreement effective January 31, 2024. Based on the fair value remeasurement performed, we recognized a gain on change in fair value of the contingent liability of $13.2 million for the twelve months ended December 31, 2023 in our consolidated statements of income.

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration